Test of the recommended dialysis dose on one-year mortality of nondiabetic maintenance hemodialysis patients; observations from a single dialysis unit
Göster/ Aç
Erişim
info:eu-repo/semantics/closedAccessTarih
2016Yazar
Şahutoğlu, TuncayKara, Ekrem
Ahbap, Elbis
Şakacı, Tamer
Koç, Yener
Baştürk, Taner
Sevinç, Mustafa
Akgöl, Cüneyt
Uçar, Zuhal Atan
Kayalar, Arzu Özdemir
Çağlayan, Feyza Bayraktar
Ünsal, Abdülkadir
Üst veri
Tüm öğe kaydını gösterKünye
Sahutoglu, T., Kara, E., Ahbap, E., Sakaci, T., Koc, Y., Basturk, T., Sevinc, M., Akgol, C., Ucar, Z. A., Ozdemir Kayalar, A., Caglayan, F. B., & Unsal, A. (2016). Test of the recommended dialysis dose on one-year mortality of nondiabetic maintenance hemodialysis patients; observations from a single dialysis unit. Renal failure, 38(8), 1174–1179. https://doi.org/10.1080/0886022X.2016.1208515Özet
Background: the optimal delivered dialysis dose has been of a great interest for the last three decades, though a clear cut point has not been reached yet. We aimed to evaluate the relationship between one-year mortality and the delivered dialysis dose, which was recommended by Kidney Disease Outcomes Quality Initiative (KDOQI), in our maintenance hemodialysis (MHD) patients.Methods: This was a single center, prospective observational study with one year of follow-up. Patients with extremes of age, BMI, residual renal function, diabetes mellitus, severe infection malignancy, and recent hospitalization within the last three months were excluded. Demographic, anthropometric, laboratory, and outcome data (mortality as the primary) were prospectively collected. Patients were classified into two groups according to baseline spKt/V levels; group 1 (n=20): spKt/V1.4, group 2 (n=60): spKt/V>1.4.Results: Median (IQR) age and hemodialysis vintage of all patients (M/F: 41/39) were 49.5 (29) years and 60 (94) months, respectively. Both groups had similar characteristics, with the exception of significantly higher BMI (24 vs. 21.7, p=0.012), serum creatinine and uric acids, and lower spKt/V (1.30 vs. 1.71, p<0.001) in group 1. Overall death occurred in seven (8.75%) patients (5 from group 1 and 2 from group 2). Patients in group 1 had significantly higher one-year mortality rate and shorter survival time (25% vs. 3.3%, p=0.003 and 43.9 vs. 47.3 weeks, p=0.003, respectively).Conclusions: Higher spKt/V (>1.4) was associated with a lower one-year mortality in this small cohort of patients.